Sphera Funds Management’s Day One Biopharmaceuticals DAWN Stock Holding History

Sphera Funds Management’s Portfolio DAWN Stock Details DAWN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-145,371	Closed	-$1.35M	–	103
2025 Q4	$1.35M	Sell	145,371 -30,000	-17%	-$251K	0.26%	82
2025 Q3	$1.24M	Hold	175,371	–	–	0.26%	91
2025 Q2	$1.14M	Sell	175,371 -159,616	-48%	-$1.1M	0.27%	84
2025 Q1	$2.66M	Hold	334,987	–	–	0.61%	51
2024 Q4	$4.24M	Sell	334,987 -12,640	-4%	-$176K	0.77%	49
2024 Q3	$4.84M	Hold	347,627	–	–	0.77%	45
2024 Q2	$4.79M	Sell	347,627 -145,000	-29%	-$2.12M	0.65%	51
2024 Q1	$8.14M	Sell	492,627 -20,373	-4%	-$305K	1.14%	31
2023 Q4	$7.49M	Sell	513,000 -17,000	-3%	-$206K	1.21%	27
2023 Q3	$6.5M	Hold	530,000	–	–	1.18%	27
2023 Q2	$6.33M	Buy	+530,000	New	+$6.92M	0.99%	37

Other funds holding DAWN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

GCL

Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

Kryger Capital London, United Kingdom $1.41B AUM 86.31% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return

Sphera Funds Management's DAWN Position: Q1 2026 in Review

Sphera Funds Management sold out of Day One Biopharmaceuticals (DAWN) in Q1 2026, closing a stake of 145,371 shares — an estimated $1.35M sold.

Sphera Funds Management first reported a position in DAWN in Q2 2023 and held it in 11 quarters. The position peaked at $8.14M in Q1 2024. 206 funds tracked by Wall St. Rank hold DAWN as of Q1 2026.

Sphera Funds Management reported no remaining Day One Biopharmaceuticals position as of Q1 2026 after selling out during the quarter.
Sphera Funds Management sold 145,371 Day One Biopharmaceuticals shares in Q1 2026, an estimated $1.35M.
Sphera Funds Management first reported a position in Day One Biopharmaceuticals in Q2 2023 and held it in 11 quarters.
Sphera Funds Management's Day One Biopharmaceuticals position peaked at $8.14M in Q1 2024.
206 funds tracked by Wall St. Rank held Day One Biopharmaceuticals as of Q1 2026.

Based on Sphera Funds Management's 13F filing for Q1 2026, filed 15 May 2026.